Basic Information
| LncRNA/CircRNA Name | CRCAL-3 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Colorectal Cancer |
| ICD-0-3 | C19.9 |
| Methods | qRT-PCR, in vitro knockdown etc. |
| Sample | Paraffin-embedded pretreatment tissue samples with complete clinicopathological information, The CRC cell lines (Lovo, RKO, sw1116, sw480, sw620, DLD-1, HCT116, and HT29) and the cell lines of normal colon epithelium (CCD112 and CCD841) |
| Expression Pattern | up-regulated |
| Function Description | Analyses on TCGA datasets showed an upregulated CRCAL-3 expression in 14 solid tumors, including CRC. PCR assay on 253 cases of CRC tissue and 114 cases of normal adjacent tissue confirmed this expression upregulation. Also, CRCAL-3 expression was exhibited by survival analyses on the 253 CRC patients, to have a negative correlation with patients' overall and progression-free survivals. PCR assay on different cell lines showed that CRC cells expressed a higher level of CRCAL-3, compared with normal colonic epithelial cells. In vitro knockdown of CRCAL-3 resulted in an obvious retardation of proliferation and migration in two CRC cell lines (HCT116 and DLD-1). Moreover, CRCAL-3 knockdown was observed in xenograft models to repress cell proliferation and enhance cisplatin sensitivity. |
| Pubmed ID | 31038794 |
| Year | 2019 |
| Title | The Expression of Long Noncoding RNA CRCAL-3 in Colorectal Cancer and Its Impacts on Cell Proliferation and Migration |
External Links
| Links for CRCAL-3 | GenBank HGNC NONCODE |
| Links for Colorectal Cancer | OMIM COSMIC |